telmisartan has been researched along with arginine vasopressin in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Heinemann, A; Horina, G; Pieber, D; Pieber, TR; Sandner-Kiesling, A | 1 |
Culman, J; Gohlke, P; Jansen, A; Rascher, W; Stangier, J; Unger, T; Weiss, S; Wienen, W | 1 |
1 review(s) available for telmisartan and arginine vasopressin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for telmisartan and arginine vasopressin
Article | Year |
---|---|
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pressor and mesenteric arterial hyporesponsiveness to angiotensin II is an early event in haemorrhagic hypotension in anaesthetised rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine Vasopressin; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Glyburide; Hemodynamics; Indomethacin; Male; Mesenteric Artery, Superior; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phenylephrine; Potassium Channels; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Regional Blood Flow; Shock, Hemorrhagic; Telmisartan; Time Factors; Vasoconstrictor Agents | 1999 |
AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine Vasopressin; Benzimidazoles; Benzoates; Blood Pressure; Blood-Brain Barrier; Drinking; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Vasoconstrictor Agents | 2001 |